|Day's Range||76.60 - 77.04|
|52 Week Range||66.93 - 83.58|
|PE Ratio (TTM)||28.96|
|Dividend & Yield||2.72 (3.71%)|
|1y Target Est||N/A|
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi await big FDA decisions in May.
The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday. AML is a cancer that originates in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.